External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy.
Bladder cancer
Brachytherapy
External beam radiotherapy combination
Prostate cancer
Smoking
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
15
11
2022
accepted:
17
03
2023
medline:
18
5
2023
pubmed:
7
4
2023
entrez:
6
4
2023
Statut:
ppublish
Résumé
To investigate the risk of bladder cancer (BCa) in patients treated with brachytherapy for prostate cancer (PCa). We retrospectively analyzed 583 patients with PCa who underwent brachytherapy with or without external beam radiotherapy (EBRT). We analyzed the disease-free survival (DFS) of BCa in patients with PCa who underwent brachytherapy with or without EBRT. We performed multivariate Cox regression analyses of DFS using age, EBRT, and Brinkman index (BI) score (number of cigarettes smoked per day × number of years smoking) ≥ 200 as variables for BCa after brachytherapy. Fourteen patients (2.4%) developed BCa after brachytherapy with or without EBRT. The percentage of high-grade urothelial carcinoma (UC) was 63.6%. A total of 85.7% of patients had non-muscle invasive BCa, and 14.3% of patients had muscle invasive BCa. DFS was longer in brachytherapy monotherapy than in combination therapy (brachytherapy + EBRT). Multivariate Cox regression analysis showed that a BI score ≥ 200 (Hazard Ratio (HR 8.61; 95% Confidence Interval (CI) 1.12-65.98) and EBRT combination (HR 3.29; 95% CI 1.03-10.52) were significantly associated with BCa development in patients with PCa treated with brachytherapy. Furthermore, patients with BI score ≥ 200 and EBRT combination had a significantly higher risk of BCa compared with patients with BI score < 200 (HR Log-rank test P = 0.010). Most cases of BCa after brachytherapy with or without EBRT are high grade and invasive. We hypothesized that the EBRT combination might be a risk factor for BCa in patients with PCa who underwent brachytherapy.
Identifiants
pubmed: 37024557
doi: 10.1007/s00345-023-04380-5
pii: 10.1007/s00345-023-04380-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1317-1321Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Cooperberg MR, Broering JM, Litwin MS et al (2004) The contemporary management of prostate cancer in the United States: lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CapSURE), a national disease registry. J Urol 171(4):1393–1401
doi: 10.1097/01.ju.0000107247.81471.06
pubmed: 15017184
Best T, Li D, Skol AD et al (2011) Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin’s lymphoma. Nat Med 17(8):941–943
doi: 10.1038/nm.2407
pubmed: 21785431
pmcid: 3229923
Boorjian S, Cowan JE, Konety BR et al (2007) Bladder cancer incidence and risk factors in men with prostate cancer: results from cancer of the prostate strategic urologic research endeavor. J Urol 177(3):883–887 (Discussion 887)
doi: 10.1016/j.juro.2006.10.071
pubmed: 17296367
Liauw SL, Sylvester JE, Morris CG, Blasko JC, Grimm PD (2006) Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Int J Radiat Oncol Biol Phys 66(3):669–673
doi: 10.1016/j.ijrobp.2006.05.016
pubmed: 16887293
Yoshida T, Kates M, Fujita K, Bivalacqua TJ, McConkey DJ (2019) Predictive biomarkers for drug response in bladder cancer. Int J Urol 26(11):1044–1053
doi: 10.1111/iju.14082
pubmed: 31370109
Sandhu JS, Vickers AJ, Bochner B, MacheleDonat S, Herr HW, Dalbagni G (2006) Clinical characteristics of bladder cancer in patients previously treated with radiation for prostate cancer. BJU Int 98(1):59–62
doi: 10.1111/j.1464-410X.2006.06182.x
pubmed: 16626308
Yee DS, Shariat SF, Lowrance WT et al (2010) Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. J Urol 183(5):1751–1756
doi: 10.1016/j.juro.2010.01.014
pubmed: 20299035
pmcid: 4295901